Chemi-Verse™ ABL2 Kinase Assay Kit

Catalog #
82220
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ ABL2 Kinase Assay Kit is designed to measure ABL2 (Abelson-Related gene protein) kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant ABL2 kinase (amino acids 38-end), kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Synonyms
Tyrosine-protein kinase ABL2, Abelson murine leukemia viral oncogene homolog 2, Abelson tyrosine-protein kinase 2, Abelson-related gene protein, Tyrosine-protein kinase ARG, ABLL, ARG, ABL-2
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator
Format
Catalog # Name Amount Storage
40417 ABL2, His-Tag* 1 µg -80°C
79334 5x Kinase Buffer 1 1.5 ml -20°C
79686 500 µM ATP 50 µl -20°C
  ABLtide (1 mg/ml) 500 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
P42684
Background

ABL2, also known as Abelson-related gene protein or ABL proto-oncogene 2, is a cytoplasmic tyrosine kinase of the Abelson tyrosine kinase family. ABLs are involved in development and cellular homeostasis and become abnormally activated in the presence of insults, such as inflammation, tissue injury, cancer, neural degeneration and other diseases. They respond to growth factors, chemokines, oxidative stress, and DNA damage by promoting cytoskeleton rearrangements. For instance, in solid tumors their activation can lead to invadopodia formation and EMT (epithelial-mesenchymal transition), which promotes metastasis and resistance to chemotherapy. Inhibition of ALB2 by allosteric inhibitors and PROTACs may prove beneficial in creating sensitivity of the patients to standard methods of cancer treatment. A deeper understanding of the mode of action of ABL2 and results of its inhibition will move the cancer therapy field forward.

References

Luttman J., et al., 2021 Cell Communications and Signaling 19:59.